Apnimed is a pharmaceutical company focused on pharmacologic therapies for obstructive sleep apnea (OSA) and related disorders. Its lead product candidate, AD109, targets key neurological pathways in OSA, reducing pathological upper airway closure during sleep. The company also develops combination therapeutics designed for OSA patients with symptoms of disturbed sleep, and other products.